The news, issued via a press release, mirrored similar news from Eli Lilly last week that it's monoclonal antibody prevented symptomatic Covid-19 infections in nursing homes.
The results represent the first 400 volunteers from the study, which is being run by the National Institute of Allergy and Infectious Diseases (NIAID) and is continuing to enroll patients. The volunteers were at high risk of infection because they lived in the same household as a Covid-19 patient. Half the patients received a placebo, and the other half received 1.2 grams of casirivimab and imdevimab, Regeneron’s antibodies.
Read the full article right here.